[Action on Hearing Loss] We support world-class hearing loss and tinnitus research and we are currently requesting proposals for the TRIH Grant that aims to support the translation of research discoveries into potential new treatments for hearing loss and /or tinnitus. It funds projects globally from both academic institutions and small/medium enterprises (SMEs).
TRIH Grant supports:
– research with a strong commercial potential that is likely to attract follow-on funding at the conclusion of the grant
– studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.
This grant does NOT support basic research into the causes and underpinning biology of hearing loss and tinnitus or the development of devices or software.
Summary of grant:
- Duration: Up to three years
- Eligibility: Applicants may be from any country and may be from academic institutions and small/medium enterprises (SMEs)
- Value *: Up to £100,000 per year.
– Expression of Interest: 20th November 2017 (5 pm GMT)
– Full application (by invitation only): 19th January 2018 (5 pm GMT)
– Funding decisions: July 2018* Please note that as a charity, it is their policy not to fund any indirect costs or the salaries of permanent employees.
Applications will be accepted in the following areas:
- Small molecule, gene or cell-based approaches for the treatment of hearing loss or tinnitus. This can include:– Studies which will enable lead optimisation and/or candidate selection.
– Pharmacokinetics/Pharmacodynamics (PKPD) studies.
– Safety/toxicology studies.
– Drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
- Research that addresses at least one of the following “TRIH Challenge” topics
– Validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach).
– Studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus.
– Preclinical model validation i.e. studies to increase the understanding of in-vivo or in-vitro model relevance to human hearing loss or tinnitus.
– Identification/validation of methods or outcomes that could be used for one or more of the following:
· Patient selection/stratification for clinical trials
· Robust measurement of treatment responses in clinical trials
This year, applications will not be accepted in the following areas:
- Basic research into the causes and underpinning biology of hearing loss and tinnitus
- The development of devices or software
- The optimization of current clinical protocols
- Health service studies
Dr. Carina Santos
Translational Research Manager, PhD
Action on Hearing LossRead more